

Sasha Mazzarello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7803014/publications.pdf>

Version: 2024-02-01

60
papers

978
citations

393982

19
h-index

500791

28
g-index

60
all docs

60
docs citations

60
times ranked

1335
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. <i>Stem Cells Translational Medicine</i> , 2018, 7, 857-866.	1.6	99
2	Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects. <i>Oncologist</i> , 2014, 19, 127-134.	1.9	72
3	Predatory Invitations from Journals: More Than Just a Nuisance?. <i>Oncologist</i> , 2017, 22, 236-240.	1.9	42
4	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021, 142, 132-140.	1.3	42
5	Defining optimal control of chemotherapy-induced nausea and vomitingâ€”based on patientsâ€™ experience. <i>Supportive Care in Cancer</i> , 2015, 23, 3341-3359.	1.0	37
6	Risk Modelâ€”Guided Antiemetic Prophylaxis vs Physicianâ€™s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 225.	3.4	37
7	Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 1-8.	1.1	33
8	Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancerâ€”a systematic review. <i>Supportive Care in Cancer</i> , 2016, 24, 3633-3650.	1.0	33
9	Conflict of interest as ethical shorthand: understanding the range and nature of â€œnon-financial conflict of interestâ€”in biomedicine. <i>Journal of Clinical Epidemiology</i> , 2020, 120, 1-7.	2.4	30
10	Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapyâ€”a systematic review. <i>Supportive Care in Cancer</i> , 2016, 24, 1583-1594.	1.0	29
11	Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. <i>SpringerPlus</i> , 2014, 3, 176.	1.2	27
12	Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1016-e1024.	2.5	26
13	Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patientsâ€”A Systematic Review. <i>Clinical Breast Cancer</i> , 2016, 16, 456-470.	1.1	26
14	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 615-624.	1.1	25
15	De-escalated administration of bone-targeted agents in patients with breast and prostate cancerâ€”A survey of Canadian oncologists. <i>Journal of Bone Oncology</i> , 2013, 2, 77-83.	1.0	24
16	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 507-517.	1.1	23
17	Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxelâ€”cyclophosphamide chemotherapy for breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 1-10.	1.1	22
18	Is This Conference for Real? Navigating Presumed Predatory Conference Invitations. <i>Journal of Oncology Practice</i> , 2017, 13, 410-413.	2.5	20

#	ARTICLE	IF	CITATIONS
19	Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. <i>Supportive Care in Cancer</i> , 2016, 24, 1563-1569.	1.0	19
20	Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. <i>Journal of Bone Oncology</i> , 2013, 2, 105-109.	1.0	18
21	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. <i>SpringerPlus</i> , 2014, 3, 577.	1.2	18
22	Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients. <i>Supportive Care in Cancer</i> , 2015, 23, 3269-3275.	1.0	17
23	A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4891-4899.	1.0	17
24	Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. <i>Systematic Reviews</i> , 2015, 4, 114.	2.5	16
25	Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 337-344.	1.1	15
26	The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 832-846.	1.8	15
27	Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. <i>Journal of Bone Oncology</i> , 2013, 2, 38-46.	1.0	14
28	A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 1-6.	0.9	13
29	Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer — An inspection of the evidence base informing clinical decision-making. <i>Cancer Treatment Reviews</i> , 2015, 41, 951-959.	3.4	12
30	A Simple Approach for Eliminating Spam. <i>Current Oncology</i> , 2016, 23, 75-76.	0.9	10
31	Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. , 2020, 47, E86-E106.		10
32	Surviving Surveys. <i>Journal of Oncology Practice</i> , 2015, 11, 44-46.	2.5	9
33	Future directions for bone metastasis research — highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016, 5, 57-62.	1.0	9
34	A comparison of policy provisions for managing “financial” and “non-financial” interests across health-related research organizations: A qualitative content analysis. <i>Accountability in Research</i> , 2020, 27, 212-237.	1.6	9
35	Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2017, 25, 1881-1886.	1.0	8
36	Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 196-204.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Risk Factors for Failure to Rescue in Myocardial Infarction after Noncardiac Surgery. <i>Anesthesiology</i> , 2020, 133, 96-108.	1.3	8
38	Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. <i>Journal of Clinical Medicine</i> , 2013, 2, 67-88.	1.0	7
39	De-Escalation of Bone-Targeted Agents for Metastatic Prostate Cancer. <i>Current Oncology</i> , 2016, 23, 77-78.	0.9	7
40	A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 371-379.	1.1	7
41	Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	7
42	A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 337-345.	1.1	7
43	Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2019, 19, e40-e47.	1.1	7
44	Filgrastim use in patients receiving chemotherapy for early-stage breast cancer—a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2018, 26, 2323-2331.	1.0	6
45	A prospective intervention to improve happiness and reduce burnout in oncologists. <i>Supportive Care in Cancer</i> , 2019, 27, 1563-1572.	1.0	6
46	A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. <i>Supportive Care in Cancer</i> , 2017, 25, 2505-2513.	1.0	5
47	Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). <i>Supportive Care in Cancer</i> , 2019, 27, 1345-1354.	1.0	5
48	Nipple discharge. <i>Cmaj</i> , 2015, 187, 599-599.	0.9	4
49	Dosing Strategies of Bone-Targeting Agents. <i>JAMA Internal Medicine</i> , 2015, 175, 1864.	2.6	4
50	Postoperative shared-care for patients undergoing non-cardiac surgery: a systematic review and meta-analysis. <i>Canadian Journal of Anaesthesia</i> , 2019, 66, 1095-1105.	0.7	4
51	Patient perceptions about potential side effects and benefits from chemotherapy agents.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6595-6595.	0.8	4
52	A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers. <i>PLoS ONE</i> , 2021, 16, e0248238.	1.1	3
53	Strategies for obtaining bone biopsy specimens from breast cancer patients — Past experience and future directions. <i>Journal of Bone Oncology</i> , 2016, 5, 180-184.	1.0	1
54	A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey) Tj ETQq0 0 OrgBT /Overlock 10 T		

#	ARTICLE	IF	CITATIONS
55	Comparison of two care schedules for monitoring of cardiotoxicity in patients receiving trastuzumab-based therapy for early-stage breast cancer: study protocol for a randomized controlled non-inferiority trial. <i>Clinical Trials in Degenerative Diseases</i> , 2017, 2, 40.	0.1	1
56	Serum activinA and TGF- β ² as biomarkers of breast cancer bone metastasis behavior.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10620-10620.	0.8	0
57	Should de-escalation of bone-targeted agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17711-e17711.	0.8	0
58	Weight control strategies in breast cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 179-179.	0.8	0
59	Optimal weight control strategies in cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10109-10109.	0.8	0
60	A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21594-e21594.	0.8	0